Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Immunomedics history
Immunomedics company history timeline
The company, which is based in Morris Plains, N.J., said the patents were counterparts to United States patents licensed to Immunomedics by the company's founder and chairman, David Goldenberg, in 1982.
Boby M. Sundoro, director of chemistry for immunomedics, was granted patent 4,680,338 for the linker.By Stacy V. JonesJuly 18, 1987
PATENTSPATENTS; A Test to Diagnose Certain CancersLEAD: Immunomedics Inc., a biotechnology company in Warren, N.J., was awarded a patent this week for a test to diagnose cancer of the lung, breast, and gastrointestinal tract.By Edmund L. AndrewsApril 8, 1989
Patents; Antibody Method Used To Locate InfectionsLEAD: Immunomedics Inc., a small biotechnology concern in Warren, N.J., has obtained a patent on a method of pinpointing infections and inflammations.By Edmund L. AndrewsMay 26, 1990
The antibody moiety of IMMU-132 was initially described in a paper published in 1993.
The company's Immuraid-CEA imager is a compound used to detect cancer left in the body after surgery.By Bloomberg NewsMay 26, 1994
SN-38 is the active metabolite of Irinotecan; an extensively studied cancer drug that was initially approved in 1996.
The third era of orphan drug designations occurred in 2008 when IMMU received 4 designations for various indications.
There was also pressure to uphold the integrity of the accelerated program that was used to approve Avastin for breast cancer in 2008.
Immunomedics began enrolling a Phase 1/2 study of IMMU-132 in February 2013.
Celldex has lost 90% of its value since May 2015.
By September 2015, venBio had acquired over 5% of shares outstanding of Cascadian Therapeutics, Inc. (Nasdaq:CASC), formerly known as Oncothyreon Inc., a high flying biotech stock that was trading in the $20 range at the time.
IMMU’s share price on April 22nd, 2016, the day of the PR, was $3.22.
In 2019, it spent more than $5 billion deepening a partnership with Belgian biotech firm Galapagos NV. Earlier this year, it paid about $5 billion for biotech company Forty Seven Inc. and its blood-cancer drug.
In 2019, the FDA postponed approval of Trodelvy, which Immunomedics said stemmed from chemistry and manufacturing issues.
In 2022, Jefferies estimates, Trodelvy sales will reach $480 million.
Rate how well Immunomedics lives up to its initial vision.
Immunomedics jobs
Do you work at Immunomedics?
Is Immunomedics' vision a big part of strategic planning?
Immunomedics competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Amgen | 1980 | $33.4B | 22,000 | 529 |
| Merck | 1891 | $64.2B | 74,000 | 1,328 |
| Zoetis | 1952 | $9.3B | 11,300 | 200 |
| Seagen | 1997 | $2.0B | 900 | - |
| Alnylam Pharmaceuticals | 2002 | $2.2B | 1,323 | 1 |
| Vertex Pharmaceuticals | 1989 | $11.0B | 3,400 | 203 |
| Gilead Sciences | 1987 | $28.8B | 11,800 | 536 |
| Regeneron | 1988 | $14.2B | 9,123 | 327 |
| Sanofi Genzyme | 1981 | $4.6B | 12,000 | - |
| Spectrum Pharmaceuticals | 2002 | $10.1M | 235 | - |
Immunomedics history FAQs
Zippia gives an in-depth look into the details of Immunomedics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Immunomedics. The employee data is based on information from people who have self-reported their past or current employments at Immunomedics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Immunomedics. The data presented on this page does not represent the view of Immunomedics and its employees or that of Zippia.
Immunomedics may also be known as or be related to IMMUNOMEDICS INC, Immunomedics, Immunomedics Inc, Immunomedics Inc. and Immunomedics, Inc.